Anxiolytic-like properties of the anandamide transport inhibitor AM404

Neuropsychopharmacology

Volumn 31, Issue 12, 2006, Pages 2652-2659

  Bortolato, Marco ^a   Campolongo, Patrizia ^b   Mangieri, Regina Anne ^a   Scattoni, Maria Luisa ^b   Frau, Roberto ^c   Trezza, Viviana ^b   La Rana, Giovanna ^d   Russo, Roberto ^d   Calignano, Antonio ^d   Gessa, Gian Luigi ^c   Cuomo, Vincenzo ^b   Piomelli, Daniele ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AM404; Anandamide; Anxiety; Conditioned place preference; Prepulse inhibition

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; ANANDAMIDE TRANSPORT INHIBITOR; APOMORPHINE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; DIAZEPAM; DIZOCILPINE; ENDOCANNABINOID TRANSPORT INHIBITOR; MORPHINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; MALE; MAZE TEST; NONHUMAN; PLACE PREFERENCE; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RAT STRAIN; STARTLE REFLEX; TRANQUILIZING ACTIVITY;

ANIMALS; ANIMALS, NEWBORN; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; ANXIETY, SEPARATION; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; BRAIN; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; MALE; MAZE LEARNING; NEURAL INHIBITION; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; STARTLE REACTION;

EID: 33746149921     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301061     Document Type: Article

References (62)

1. Abduljawad KA, Langley RW, Bradshaw CM, Szabadi E (1997). Effects of clonidine and diazepam on the acoustic startle response and on its inhibition by 'prepulses' in man. J Psychopharmacol 11: 29-34.
2. Alger BE (2004). Endocannabinoids: getting the message across. Proc Natl Acad Sci USA 101: 8512-8513.
3. Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgansberger W et al (2004). Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 24: 9953-9961.
4. Bahri T, Amir T (1994). Effect of hashish on vigilance performance. Percept Mot Skills 78: 11-16.
5. Beinfeld MC, Connolly K (2001). Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci Lett 301: 69-71.
6. Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G et al (2000). Reversal of dopamine D(2). receptor responses by an anandamide transport inhibitor. J Neurosci 20: 3401-3407.
7. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277: 1094-1097.
8. Bortolato M, Aru GN, Frau R, Orru M, Luckey GC, Boi G et al (2005). The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology 177: 264-271.
9. Bowling SL, Bardo MT (1994). Locomotor and rewarding effects of amphetamine in enriched, social, and isolate reared rats. Pharmacol Biochem Behav 48: 459-464.
10. Cagiano R, Barfield RJ, White NR, Pleim ET, Weinstein M, Cuomo V (1988). Subtle behavioural changes produced in rat pups by in utero exposure to haloperidol. Eur J Pharmacol 157: 45-50.
11. Cahill L, McGaugh JL (1998). Mechanisms of emotional arousal and lasting declarative memory. Trends Neurosci 21: 294-299.
12. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR et al (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371-9376.
13. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87.
14. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatr 57: 594-608.
15. de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Viso A, Lopez-Rodriguez ML, Ramos JA (2002). UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur J Pharmacol 449: 99-103.
16. Désarnaud F, Cadas H, Piomelli D (1995). Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem 270: 6030-6035.
17. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC et al (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686-691.
18. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G et al (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597). Effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352-358.
19. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A et al (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 101: 8756-8761.
20. Fernandez-Espejo E, Galan-Rodriguez B (2004). Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor. Psychopharmacology 175: 220-224.
21. Freund TF, Katona I, Piomelli D (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066.
22. Gardner EL (2005). Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81: 263-284.
23. Gerdeman GL, Ronesi J, Lovinger DM (2002). Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5: 446-451.
24. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND (1999). Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288: 478-483.
25. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2: 358-363.
26. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG (2003). Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100: 4269-4274.
27. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M et al (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102: 18620-18625.
28. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B et al (2002). Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99: 6370-6375.
29. Haller J, Varga B, Ledent C, Freund TF (2004). CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15: 299-304.
30. Hill MN, Gorzalka BB (2005). Pharmacological enhancement of cannabinoid CB (1) receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 15: 593-599.
31. Hillard CJ, Edgemond WS, Campbell WB (1995). Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J Neurochem 64: 677-683.
32. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB (1997). Accumulation of N-arachidonoylethanolamine (anandamide). into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69: 631-638.
33. Hillard CJ, Jarrahian A (2003). Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 140: 802-808.
34. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley DB, Mangieri RA et al (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112.
35. Hollister LE (1998). Health aspects of cannabis: revisited. Int J Neuropsychopharmacol 1: 71-80.
36. Justinova Z, Goldberg SR (2005). The abuse potential of the endocannabinoid transport inhibitor AM404: self-administration by squirrel monkeys. 15th Annual Symposium on the cannabinoids, 2005, Clearwater, USA.
37. Justinova Z, Solinas M, Tanda G, Redhi GH, Goldberg SR (2005). The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci 25: 5645-5650.
38. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
39. Kelley BG, Thayer SA (2004). Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. Eur J Pharmacol 496: 33-39.
40. Koelega HS (1989). Benzodiazepines and vigilance performance: a review. Psychopharmacology 98: 145-156.
41. Larsson F, Winblad B, Mohammed AH (2002). Psychological stress and environmental adaptation in enriched vs impoverished housed rats. Pharmacol Biochem Behav 73: 193-207.
42. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL et al (2004). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311: 441-448.
43. Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying BP et al (2005). Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad USA 102: 17852-17857.
44. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR et al (1997). Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8: 491-496.
45. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. Neuron 34: 13-25.
46. Nicholson RA, Liao C, Zheng J, David LS, Coyne L, Errington AC et al (2003). Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res 978: 194-204.
47. Ortega-Gutierrez S, Hawkins EG, Viso A, Lopez-Rodriguez ML, Cravatt BF (2004). Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry 43: 8184-8190.
48. Palmer SL, Thakur GA, Makriyannis A (2002). Cannabinergic ligands. Chem Phys Lipids 121: 3-19.
49. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004). Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145: 5431-5438.
50. Pellow S, Chopin P, File SE, Briley M (1985). Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149-167.
51. Piomelli D (2005). The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6: 672-679.
52. Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ et al (1999). Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA 96: 5802-5807.
53. Renner MJ, Rosenzweig MR (1987). The golden-mantled ground squirrel (Spermophilus lateralis). As a model for the effects of environmental enrichment in solitary animals. Dev Psychobiol 20: 19-24.
54. Smith MA, Bryant PA, McClean JM (2003). Social and environmental enrichment enhances sensitivity to the effects of kappa opioids: studies on antinociception, diuresis and conditioned place preference. Pharmacol Biochem Behav 76: 93-101.
55. Steffens M, Szabo B, Klar M, Rominger A, Zentner J, Feuerstein TJ (2003). Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience 120: 455-465.
56. Swerdlow NR, Braff DL, Geyer MA (2000). Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 11: 185-204.
57. Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP (2001). Antagonism of CRF2 receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902: 135-142.
58. Tzavara ET, Wade M, Nomikos GG (2003). Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 23: 9374-9384.
59. Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T (1995). Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 270: 23823-23827.
60. Urigüen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J (2004). Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46: 966-973.
61. Weidenfeld J, Feldman S, Mechoulam R (1994). Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59: 110-112.
62. Zygmunt PM, Chuang H, Movahed P, Julius D, Hogestatt ED (2000). The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 396: 39-42.